Magnetic Metallic Crystals Technology for Advanced Invitro Diagnostics


Advanced Diagnostics Simplified

Fast BT is simplifying advanced invitro diagnostics through its Magnetic-Metallic-Crystals technology.  Billions of magnetic and metal nanoparticles are crystalized around single molecular-targets like bacteria, viruses or biomarkers. Once trace amounts of these molecular-targets are trapped inside large 3D Magnetic-Metallic-Crystals, they can be easily detected through low-cost battery powered electric devices like potentiostats.


Our mission is to make advanced diagnostics easily accessible to everyone everywhere,  for saving lives, or for creating a safer environment, or for increasing economic output.  

At Fast BT we are rethinking advanced diagnostics for the next deadly pandemic, which is only inevitable as we continue to move towards an increasingly hyper connected world. 

Join us if you share our vision


Advanced Diagnostics 

Covid19 continues to devastate our world, killing millions and shrinking economic productivity in trillions. In Vitro advanced diagnostics are our first line of defenses in containing a potential pandemic from spreading across the globe. Today, we do not have a diagnostic technology that can quickly screen large numbers of people, for example in a busy airport or any other site bustling with human activity in close proximity. Billions will die if the next pandemic were to be triggered by a virus that is as transmissible as Covid19 and as deadly as Ebola.

To stop the next deadly pandemic in its tracks, we must have intelligent advanced diagnostic devices everywhere - and they must be high-throughput devices cheap to mass-produce, battery powered and compact in size, automated and user-friendly so that anyone can operate them anywhere. Next time around, we must not hold ourselves hostage to advanced diagnostics that can only be performed in well-equipped laboratories.


We believe our technology of
is a step in the right direction.

Let us rethink advanced diagnostics together by asking the right questions, and start building a safer and a more prosperous world. 

Today, we do not have a diagnostic technology that can quickly screen large numbers of people, for example in a busy airport or any other site bustling with human activity in close proximity. We need a diagnostic technology that is easy and economical to mass-manufacture on short notice, compact enough that it can be easily dispatched to wherever it is needed, robust enough that it works equally well on a mountain top or on a desert plane, and automated enough for anyone to operate.

Advanced Blood Culture System

As a first use-case demonstration of our Magnetic-Metallic-Crystals technology, we are creating an advanced blood culture system for detecting sepsis (blood poisoning) within hours of infection compared to 2 – 5 days required by the current state of the art blood culture test. Unlike traditional blood-culture tests, which are slow at detecting bacterial growth, our advanced blood culture system captures low bacterial growth within a suspension of Magnetic-Metallic-Crystals, making it feasible to detect sepsis at very early stages.


Advanced Blood Culture Test

Results in 3-4 hours

Traditional Blood Culture Test

Results in 2-5 days

Our innovation of Magnetic-Metallic-Crystals is poised not only to save lives through early diagnosis of sepsis, but is also aimed at improving the operating efficiencies of healthcare systems worldwide.



By providing fast and accurate diagnosis of sepsis, we aim to empower clinicians to intervene with effective antibiotic treatments at early stages of sepsis, as each hour of delay in administering the right antibiotic reduces the survival chances of sepsis patients by roughly ~8%. 


Save lives . Save costs

Delayed sepsis diagnosis places enormous strain on hospital’s resources in managing severe sepsis patients, who typically occupy a large portion of available beds within ICUs (intensive care units). For hospitals in the EU and US alone, cumulative costs in managing consequences of delayed sepsis diagnosis exceed 100 billion euros annually.

Supported by

EF logo 2.png